Last reviewed · How we verify
Epirubicin, CTX, Paclitaxel
This is a combination chemotherapy regimen where epirubicin and paclitaxel are topoisomerase II and microtubule-targeting agents respectively, used together to inhibit cancer cell division and induce apoptosis.
This is a combination chemotherapy regimen where epirubicin and paclitaxel are topoisomerase II and microtubule-targeting agents respectively, used together to inhibit cancer cell division and induce apoptosis. Used for Breast cancer (likely early-stage or metastatic, based on typical EC-P regimen use).
At a glance
| Generic name | Epirubicin, CTX, Paclitaxel |
|---|---|
| Sponsor | Chinese Academy of Medical Sciences |
| Drug class | Combination chemotherapy (anthracycline + taxane + alkylating agent) |
| Target | Topoisomerase II (epirubicin), β-tubulin/microtubules (paclitaxel), DNA alkylation (cyclophosphamide) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Epirubicin is an anthracycline that intercalates into DNA and inhibits topoisomerase II, preventing DNA unwinding and causing double-strand breaks. Paclitaxel is a taxane that stabilizes microtubules and prevents their depolymerization, disrupting mitotic spindle formation. CTX likely refers to cyclophosphamide, an alkylating agent that cross-links DNA. Together, these agents provide synergistic cytotoxic effects against rapidly dividing cancer cells.
Approved indications
- Breast cancer (likely early-stage or metastatic, based on typical EC-P regimen use)
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Nausea and vomiting
- Alopecia
- Peripheral neuropathy
- Cardiotoxicity
- Mucositis
Key clinical trials
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) (PHASE3)
- A Single-Arm, Single-Center, Phase II Clinical Study of Camrelizumab Combined With Radiochemotherapy as Neoadjuvant Therapy for Early-Stage Triple-Negative Breast Cancer (NA)
- LifEStyle Intervention to Enhance Efficacy of Neoadjuvant Therapy in Patients With Triple Negative Breast Cancer (PHASE2)
- Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03) (PHASE2)
- QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Triple-Negative Breast Cancer (PHASE2)
- Posaconazole Plus PD-1 Inhibitors and Chemotherapy vs PD-1 Inhibitors and Chemotherapy in Neoadjuvant Therapy for Triple Negative Breast Cancer (PHASE2)
- A Clinical Study of Boserolimab (MK-5890) With Pembrolizumab and Chemotherapy in People With Early Triple-Negative Breast Cancer (MK-5890-003) (PHASE2)
- Phase II Exploratory Study of Toripalimab Combined With SBRT in HER2-Negative Breast Cancer Patients With Insensitivity to Neoadjuvant Chemotherapy (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Epirubicin, CTX, Paclitaxel CI brief — competitive landscape report
- Epirubicin, CTX, Paclitaxel updates RSS · CI watch RSS
- Chinese Academy of Medical Sciences portfolio CI